Press releases

 

  • DECEMBER 11, 2013

Inserm Transfert and GSK sign a worldwide license agreement on novel immune checkpoint modulators for the treatment of cancer

Downloadpdf 

  • OCTOBER 22, 2013

DBV Technologies Forms Research Collaboration with Inserm to Develop Viaskin® for Refractory Hemophilia A Disease

Downloadpdf

  • FEBRUARY 6, 2013

Inserm Transfert and MassBio announce a partnership to foster innovation, technology transfer and entrepreneurship between France and Massachusetts (USA).

Downloadpdf

  • JANUARY 7, 2013

QIAGEN Marseille acquires exclusive rights from Inserm Transfert SA and Inserm on HSP110 mutations for colorectal cancer.

Downloadpdf

 

 


Increase font size Default font size Decrease font size